Clinical Trial Update: BPDO-1603 Intervention Trial in Patients With Moderate-to-severe Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update for BPDO-1603 in moderate-to-severe Alzheimer's disease is reported with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• BPDO-1603

Snippet

Sponsor: Hyundai Pharmaceutical Co., LTD. | Conditions: Moderate-to-severe Alzheimer's Disease | Phase 3 | Status: UNKNOWN